Agilus Diagnostics has joined forces with Lucence, a molecular diagnostics company, to revolutionize cancer diagnostics and personalized treatment in India. This strategic partnership will integrate Lucence’s advanced molecular testing technologies into Agilus’ extensive laboratory network, enhancing cancer detection, treatment decision-making, and patient monitoring.
As part of this collaboration, Agilus Diagnostics will incorporate Lucence’s innovative molecular testing solutions into its oncology diagnostic services. One of the key offerings, LiquidHALLMARK, is an ultra-sensitive next-generation sequencing liquid biopsy that examines circulating tumor DNA (ctDNA) and circulating tumor RNA (ctRNA) for clinically significant biomarkers across multiple cancer types. The test identifies actionable mutations in 80 ctDNA genes and 37 ctRNA fusions, aiding in precision oncology.
By leveraging Lucence’s proprietary liquid biopsy technology, Agilus Diagnostics aims to expand its oncology services, making advanced cancer screening, recurrence monitoring, and treatment personalization more accessible across India. With this integration, the company seeks to improve early cancer detection and enhance patient outcomes nationwide.
